New growth model
Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Kripa Mahalingam - July 26, 2019
Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs
N Mahalakshmi - July 16, 2019
The Comeback Plan
Lupin is betting on its specialty drugs business to counter the pricing pressures in the US generics market
Khushboo Balani - October 03, 2017